(Total Views: 531)
Posted On: 09/21/2020 1:06:41 PM
Post# of 148917
Enrollment for most of CYDY’s trials have been slow. The cancer trial was slow to enroll even before COVID19 and should have resumed normal enrollment by now.
I don’t share your interpretation of NP’s comments on “no strength of signal.” He was ready to file the BTD earlier this year on 2 patients and now has at least 12-15 patients on leronlimab for a number of months. He has also been quiet regarding the trial which is not typical NP. I’m not saying leronlimab doesn’t work for mTNBC, maybe the 350 or 525 dose isn’t showing efficacy, but based on NP’s past history and current comments, I don’t think we’re seeing the results he/we expected.
I don’t share your interpretation of NP’s comments on “no strength of signal.” He was ready to file the BTD earlier this year on 2 patients and now has at least 12-15 patients on leronlimab for a number of months. He has also been quiet regarding the trial which is not typical NP. I’m not saying leronlimab doesn’t work for mTNBC, maybe the 350 or 525 dose isn’t showing efficacy, but based on NP’s past history and current comments, I don’t think we’re seeing the results he/we expected.
(0)
(1)Scroll down for more posts ▼
